Basic and clinical studies on SY5555 in the urological field

• Published in: CHEMOTHERAPY Vol. 42; no. Supplement1; pp. 475 - 484
• Main Authors: Hayashi, Toshihide, Watanabe, Toyohiko, Takenaka, Tadasu, Hata, Kazuhiro, Ono, Noriaki, Kumon, Hiromi, Ohmori, Hiroyuki, Kondo, Katsuyoshi, Ohasi, Teruhisa, Akaeda, Teruaki, Katayama, Yasuhiro
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1994
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.42.Supplement1_475

We studied the antibacterial activity and clinical efficacy of SY5555, a new oral penem antibiotic, in the urological field. 1) Antibacterial activity: We determined the MICs of SY5555 against 210 clinically isolated strains of 14 species from urinary tract infections, and compared them with those of cefaclor (CCL), cefixime (CFIX) and ofloxacin (OFLX). Against gram-positive organisms, the overall antibacterial activity of SY5555 was superior to that of other antibiotics. Against gram-negative organisms the activity of SY5555 was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Thirteen patients with acute uncomplicated cystitis (AUC) and 17 patients with chronic complicated urinary tract infections (C-UTI) were treated with SY5555. In 11 cases of AUC, the overall clinical efficacy rate according to the criteria of the Japanese UTI Committee was 100% and all 12 strains were eradicated bacteriologically. In 15 cases of C-UTI, the overall clinical efficacy rate according to the same criteria was 73.3%. Bacteriologically, 16 of 18 strains (88.9%) were eradicated. 3) Side effects: No side effects were observed in 30 cases, and no abnormal laboratory findings were noted in 24 cases